The Link Between Endocrine Therapy and Metabolic Risks

Adjuvant endocrine therapy serves as a cornerstone for managing estrogen receptor-positive early breast cancer. However, this therapy often leads to adverse effects on metabolic health in breast cancer. Consequently, patients may experience weight gain, insulin resistance, and dyslipidemia. Furthermore, these metabolic changes increase the risk of cardiovascular disease. Poor metabolic status might also influence long-term breast cancer outcomes. Therefore, researchers developed the EMETA-study to investigate early metabolic shifts during treatment.

Improving Metabolic Health in Breast Cancer Monitoring

Interestingly, traditional definitions of metabolic syndrome often lack the sensitivity required for early detection. Most clinicians rely on dichotomous thresholds that might miss subtle physiological changes. Specifically, the EMETA-study explores expanded metabolic health classifications. These include exploratory measures like the EMETA score and the extended MetS definition. Additionally, these tools incorporate low-density lipoprotein cholesterol and body mass index. Consequently, this approach may help identify patients at higher risk for cardiometabolic complications more effectively.

Research Methodology and the EMETA Score

This single-center prospective observational study takes place at Aarhus University Hospital in Denmark. Specifically, researchers enrolled women aged 18 or older with early-stage breast cancer. These participants started adjuvant endocrine therapy but had no pre-existing diabetes. The team assessed metabolic health at baseline and again after three months. Furthermore, they used biometric measurements and non-fasting blood samples to collect data. Moreover, the study aligns with routine clinical care to minimize additional patient visits. Ultimately, the results will help validate expanded metabolic measures in larger cohorts.

Frequently Asked Questions

How does endocrine therapy affect metabolic health?

Endocrine therapy can disrupt hormonal balance, which often leads to weight gain and insulin resistance. Additionally, some patients experience changes in their lipid profiles and blood pressure.

Why is the 3-month follow-up significant?

A 3-month follow-up captures early metabolic changes while fitting into routine clinical schedules. Furthermore, identifying these shifts early allows for timely intervention to prevent long-term cardiovascular issues.

What is the goal of the EMETA-study?

The study aims to evaluate early metabolic effects and compare different classification approaches. Consequently, it seeks to provide better tools for identifying patients at risk of cardiometabolic complications.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional relationship. Refer to the latest local and national guidelines for clinical practice.

References

Nissen L et al. Exploring the Impact of Initiating Endocrine Therapy on Metabolic Health in Early Breast Cancer: Protocol for the Prospective Follow-Up EMETA-Study. JMIR Res Protoc. 2026 Mar 25. doi: 10.2196/78589. PMID: 41880605.

Wellberg EA, et al. Diabetes mellitus in breast cancer survivors: metabolic effects of endocrine therapy. Nat Rev Endocrinol. 2023;19(12):728-745. doi: 10.1038/s41574-023-00899-0.

Li Y, et al. Lipid changes during endocrine therapy in early-stage breast cancer patients. Lipids Health Dis. 2024;23(1):9. doi: 10.1186/s12944-024-02002-6.